Thursday, October 12, 2006

Updated Safety Information on Ketek (telithromycin) and hepatic events, aggravation of myasthenia gravis and syncope

From Health Canada:
Sanofi-aventis Canada Inc. in consultation with Health Canada would like to inform you of important updated safety information regarding KETEK (telithromycin) tablets. Based on information in published case reports* and post-market adverse event reports, the Canadian Product Monograph has been revised to include information on severe and sometimes fatal hepatotoxicity in patients taking KETEK. The Product Monograph also includes updated information regarding syncope (loss of consciousness) and the use of KETEK in patients with myasthenia gravis.

For Health Professionals
For the Public

No comments: